Earlier low-dose TBI or DST overcomes CD8+ T-cell-mediated alloresistance to allogeneic marrow in recipients of anti-CD40L

Am J Transplant. 2004 Jan;4(1):31-40. doi: 10.1046/j.1600-6135.2003.00272.x.

Abstract

Treatment with a single injection of anti-CD40L (CD154) monoclonal antibody (mAb) and fully mismatched allogeneic bone marrow transplant (BMT) allows rapid tolerization of CD4+ T cells to the donor. The addition of in vivo CD8 T-cell depletion leads to permanent mixed hematopoietic chimerism and tolerance. We now describe two approaches that obviate the requirement for CD8 T-cell depletion by rapidly tolerizing recipient CD8 T cells in addition to CD4 cells. Administration of donor-specific transfusion (DST) to mice receiving 3 Gy total body irradiation (TBI), BMT and anti-CD40L mAb on day 0 uniformly led to permanent mixed chimerism and tolerance, compared with only 40% of mice receiving similar treatment without DST. In the absence of DST, moving the timing of 3 Gy TBI to day -1 or day -2 instead of day 0 led to rapid (by 2 weeks) induction of CD8+ cell tolerance, and also permitted uniform achievement of permanent mixed chimerism and donor-specific tolerance in recipients of anti-CD40L and BMT on day 0. These nontoxic regimens overcome CD8+ and CD4+ T-cell-mediated alloresistance without requiring host T-cell depletion, permitting the induction of permanent mixed chimerism and tolerance.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / chemistry
  • Bone Marrow Transplantation / methods*
  • CD4-Positive T-Lymphocytes / immunology
  • CD40 Ligand / chemistry
  • CD40 Ligand / immunology*
  • CD8-Positive T-Lymphocytes / immunology*
  • Cell Lineage
  • Combined Modality Therapy / methods*
  • Female
  • Flow Cytometry
  • Lymphocytes / immunology
  • Lymphocytes / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Skin / metabolism
  • Spleen / cytology
  • T-Lymphocytes / immunology
  • Time Factors
  • Transplantation, Homologous
  • Whole-Body Irradiation*

Substances

  • Antibodies, Monoclonal
  • CD40 Ligand